A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.

被引：0
|
作者：
Pilotto, S. [1 ]
Grizzi, G. [1 ]
Sperduti, I. [2 ]
Simbolo, M. [3 ]
Vicentini, C. [3 ]
Calio, A. [3 ]
Caccese, M. [1 ]
Mafficini, A. [3 ]
Carbognin, L. [1 ]
Corbo, V. [3 ]
Gkountakos, A. [3 ]
Santo, A. [1 ]
Infante, M. [4 ]
Brunelli, M. [3 ]
Scarpa, A. [3 ]
Tortora, G. [1 ]
Bria, E. [5 ]
机构：
[1] Univ Verona, Aoui, Med Oncol, Verona, Italy
[2] Regina Elena Inst Canc Res, Rome, Italy
[3] Univ & Hosp Trust Verona, Sect Anat Pathol, Dept Diagnost & Publ Hlth, Verona, Italy
[4] Osped Borgo Trento, Univ & Hosp Trust, Verona, Italy
[5] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, Div Med Oncol, Rome, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Genomic signature; advanced NSCLC; Immunotherapy resistance;
D O I：
10.1016/j.jtho.2018.08.1236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-12
引用
收藏
页码：S734 / S735
页数：2
相关论文
共 50 条
  • [1] Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
    Pilotto, S.
    Grizzi, G.
    Sperduti, I.
    Simbolo, M.
    Vicentini, C.
    Calio, A.
    Caccese, M.
    Mafficini, A.
    Carbognin, L.
    Corbo, V.
    Gkountakos, A.
    Santo, A.
    Infante, M.
    Brunelli, M.
    Scarpa, A.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] JAK2/STAT2/STAT3 Are Required for Myogenic Differentiation
    Wang, Kepeng
    Wang, Chihao
    Xiao, Fang
    Wang, Haixia
    Wu, Zhenguo
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (49) : 34029 - 34036
  • [3] N-acetylcysteine modulation of JAK2 and JAK3 results in decreased STAT3 activation in human B lymphocytes
    Bonnaure, Guillaume
    Neron, Sonia
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [4] STAT3 IS ACTIVATED BY JAK2 INDEPENDENT OF KEY ONCOGENIC DRIVER MUTATIONS IN NSCLC
    Weiss, Glen J.
    Looyenga, Brendan D.
    Hutchings, Danielle
    Cherni, Irene
    Kingsley, Chris
    Lorenzo, Carlos D.
    Edwards, David K.
    Sridhar, Shravan
    Mackeigan, Jeffrey P.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S682 - S683
  • [5] Lipocalin-2 promotes NSCLC progression by activating the JAK2/STAT3 signaling pathway
    Jinjin Zhang
    Qin Xu
    Gengyun Sun
    Journal of Translational Medicine, 23 (1)
  • [6] JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting
    Overmoyer, B. A.
    Almendro, V.
    Shu, S.
    Peluffo, G.
    Park, S. Y.
    Nakhlis, F.
    Bellon, J. R.
    Yeh, E. D.
    Jacene, H. A.
    Hirshfield-Bartek, J.
    Polyak, K.
    CANCER RESEARCH, 2012, 72
  • [7] Targeting the JAK2/STAT3 pathway in ovarian cancer
    Gritsina, Galina
    Xiao, Fang
    O'Brien, Shane W.
    Maglaty, Marisa A.
    Xu, Ren-Huan
    Sigal, Luis J.
    Litwin, Samuel
    Connolly, Denise C.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Targeting the JAK2/STAT3 axis in Alzheimer's disease
    Chiba, Tomohiro
    Yamada, Marina
    Aiso, Sadakazu
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (10) : 1155 - 1167
  • [9] JAK2/STAT3 pathway as a therapeutic target in ovarian cancers
    Yoshikawa, Tomoyuki
    Miyamoto, Morikazu
    Aoyama, Tadashi
    Soyama, Hiroaki
    Goto, Tomoko
    Hirata, Junko
    Suzuki, Ayako
    Nagaoka, Isao
    Tsuda, Hitoshi
    Furuya, Kenichi
    Takano, Masashi
    ONCOLOGY LETTERS, 2018, 15 (04) : 5772 - 5780
  • [10] The roles of JAK2/STAT3 signaling in fusion of the secondary palate
    Yoshida, Naoki
    Inubushi, Toshihiro
    Hirose, Takumi
    Aoyama, Gozo
    Kurosaka, Hiroshi
    Yamashiro, Takashi
    DISEASE MODELS & MECHANISMS, 2023, 16 (10)
12345